Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
Aldena Therapeutics Selects PCI Pharma Services to Manufacture & Distribute Innovative Investigational Treatment for Dermatological Diseases
Aldena Therapeutics has chosen PCI Pharma Services (PCI) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for….
Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO
Daré to receive $1.8-million payment; eligible for additional potential milestone payments of up to $180 million and tiered double-digit royalties based on net sales…..
Ocular Therapeutix Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
Ocular Therapeutix, Inc. recently announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the company’s axitinib intravitreal...PLACENTA-ON-A-CHIP - The Future of Drug Discovery In Women’s Health
Hagar Labouta, PhD, presents how researchers continue to increase the complexity of their placenta-on-a-chip models and, as their research progresses, they are confident this technology will aid the development of novel therapies to treat a wide range of maternal and fetal conditions.
Biora Therapeutics Announces Submission of IND Application for BT-600 Program Featuring NaviCap Ingestible Drug Delivery Device
Biora Therapeutics, Inc. recently announced submission of an Investigational New Drug (IND) application with the US FDA that supports the...BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Trioxide Treatment Supporting Clinical Trial for Systemic Sclerosis
BioSenic recently announced publication of data providing additional key indications of its lead API (Active Pharmaceutical Ingredient) arsenic trioxide (ATO)...Immatics & Moderna Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Immatics, NV, and Moderna, Inc. recently announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet….
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement With Giiant Pharma for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
Palisade Bio, Inc. recently announced it has entered into a licensing agreement with Giiant Pharma, Inc., providing the company with the exclusive worldwide rights to develop, manufacture, and commercialize….
SPECIAL FEATURE - Injection Devices: Designing in Sustainability, Usability & Digitization for Patient Compliance
Contributor Cindy H. Dubin, in this exclusive annual feature, highlights how leading device and drug companies are working to address the challenges of usability, sustainability, and technology to increase patient compliance.
Biostax Signs Collaboration Agreement With Immgenuity to Pursue Remission in HIV
Immune Therapeutics, Inc. d/b/a Biostax Corp. recently announced the signing of a research collaboration agreement with Immgenuity, Inc. The joint...
